SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the launch of a secondary public offering of its common stock. Certain stockholders of Catalent (the “Selling Stockholders”) are offering for sale to the public 10.0 million shares of Catalent’s common stock owned by them. Catalent is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.

Goldman, Sachs & Co. is acting as underwriter for the offering.